Phase 2 Study: Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer (NCT04251416), read in Clinical Cancer Research. buff.ly/Q1lzyDZ
AACR Journals
@aacrjournals.bsky.social
The American Association for Cancer Research’s 10 peer-reviewed journals provide a renowned, respected forum for publishing the most innovative cancer science, encompassing the full spectrum of basic, translational, clinical, and epidemiological research.
Read the Phase 2 Study: Combination Immunotherapy in Biliary Tract Cancer (NCT04969887, MoST-CIRCUIT), read in Clinical Cancer Research. buff.ly/MO1jHGm
From the August issue of Cancer Immunology Research: Low-Strength Type I Interferon Signaling Promotes CAR T-cell Treatment Efficacy buff.ly/q8vD2hi
First-in-Human Study: Cell-Based EPPs for Localized IL-2 in Ovarian Cancer (NCT05538624), read in Clinical Cancer Research. buff.ly/KShrh3q
Watch our interview with Tomasz M. Beer, MD, recipient of the 2026 Cancer Prevention Research Award for Outstanding Journal Article, to learn more about his research and ongoing work in multicancer early detection: buff.ly/R9dQCUp
Cancer Immunology Research articles featured in the spotlight⬇️ KRAS Inhibition Modulates Antitumor Immune Response🔗 doi.org/10.1158/2326... CAR T Cells Target O-Glycosylated Fibronectin🔗 doi.org/10.1158/2326... Peripheral Biomarkers of Excellent Response to Anti–PD-(L)1🔗 doi.org/10.1158/2326...
Coordinated Immune Activation Following KRAS Inhibition in Syngeneic Models Reveals Molecular Pathways that Potentiate and Limit Antitumor Immunity
Targeting the MAPK pathway via KRAS and MEK inhibition exhibits distinct cell-specific properties and responses that differentially modulate antitumor immunity.
doi.org
ACIR@acir-org.bsky.social · 2d agoNew research shows that melanocytes utilize PD-L1 to protect themselves from immune-mediated clearance of UV-mutated cells acir.org/weekly-dige...
Phase 1b Study: Intramuscular Neoantigen Vaccines in Melanoma and RCC (TCTR20191003001). Read in Clinical Cancer Research. buff.ly/sXZaxZg
From Blood Cancer Discovery: Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia buff.ly/eq2nAfB
Read about the Phase 2 Study: Encapsulated Rapamycin to Reduce Polyp Burden Associated with Familial Adenomatous Polyposis (NCT04230499), in Clinical Cancer Research. buff.ly/IZG7Zzh
Read about the Phase 1 Study: Ipatasertib plus Atezolizumab Enhances PI3K/AKT Pathway Immune Responses in Solid Tumors and Refractory Glioblastoma (NCT03673787), in Clinical Cancer Research. buff.ly/NRM0Ylt
"The journal selection process was straightforward, aligning well with our research focus." -Minah Kim, Cancer Research Author See more of what our authors are saying about publishing with the Journals. buff.ly/7x8ra8e
Michele Hartsough, PhD, Senior Editor of Cancer Discovery, is excited to meet with the community at the Cold Spring Harbor Laboratory Meeting: Mechanisms & Models of Cancer. If you have a question about the Journals or want to discuss your research, reach out to her at michele.hartsough@aacr.org.
Kevin Burton, PhD, Senior Associate Editor of Cancer Research, is excited to meet with the community at the Cold Spring Harbor Laboratory Meeting: Mechanisms & Models of Cancer. If you have a question about the Journals or want to discuss your research, reach out to him at kevin.burton@aacr.org.
Check out the Myeloid Neoplasms collection, highlighting recent advances in fundamental and clinical research on myeloid neoplasms published in Blood Cancer Discovery. buff.ly/HrAs2a0
Read about the Phase 1/2b Study: TME Gene Engineering with LOAd703 of Solid Malignancies (NCT03225989), in Clinical Cancer Research buff.ly/5mXlqCN
In this month's issue of Cancer Epidemiology, Biomarkers & Prevention, read, Cancer-Related Pain and Sexual Orientation and Gender Identity: An Intersectional Approach. buff.ly/si9Zms9
Did you know that Cancer Research Communications offers a home for high-quality pilot studies, hypothesis-generating work, and stepwise advances? Learn more about @theaacr.bsky.social's #OpenAccess, peer-reviewed journal: buff.ly/QbODtSF
Read, Dihydropyrimidine Dehydrogenase Testing: From Pharmacogenomics to Equitable Practice, in Clinical Cancer Research. buff.ly/3m6S91T
Read, Positive Predictive Value of Symptoms for Early-Onset Colorectal Cancer, in Cancer Epidemiology, Biomarkers & Prevention. buff.ly/49juzOv
Read about the Phase 2 Study: Ceralasertib ± Durvalumab in PD-(L)1 Resistant Melanoma (MONETTE, NCT05061134), in Clinical Cancer Research. buff.ly/xN5l0Ji
Read about BI 1701963, a SOS1 inhibitor, in KRAS-mutant solid tumors (NCT04111458, NCT04835714, NCT04627142), in Clinical Cancer Research: buff.ly/ys6zFFW
Amplify your research impact with the power of simultaneous publication. Learn more: buff.ly/xFawu3Z
Read the Prospective Study: ctDNA for Recurrence Prediction in Soft Tissue Sarcoma (NCT03818412), in Clinical Cancer Research. buff.ly/Hxads5F
Nominations for the inaugural Cancer Immunology Research Early Career Award are open! View criteria and be the first to submit a nomination: buff.ly/S4S2GwE
Molecular Cancer Therapeutics is an ideal venue to present findings related to innovative cancer therapeutics under preclinical or early clinical investigation. Learn more: buff.ly/FleTsdi
Read, Dihydropyrimidine Dehydrogenase Testing: From Pharmacogenomics to Equitable Practice, in Clinical Cancer Research. buff.ly/NrKWNzm
Read the new commentary in Clinical Cancer Research! Engineering and Improving Anti-CTLA-4 Checkpoint Inhibitors. buff.ly/vDdXDCn
In a phase 1 trial, Haldar, Huff, et al. treated 20 volunteers with high-risk of PDAC development (based on family history or genetics, plus radiographic indication of a precursor lesion/cyst) with [...] @aacrjournals.bsky.social @hopkinsmedicine.bsky.social bit.ly/4qeqDlE
